普拉瓦斯塔丁在患有血管疾病风险的老年人中 (PROSPER):一种随机对照试验
James Shepherd1, Gerard J Blauw, Michael B Murphy
1University Department of Pathological Biochemistry, University of Glasgow, Royal Infirmary, Scotland, Glasgow, UK. jshepherd@gri-biochem.org.uk
Lancet (London, England)
|November 30, 2002
概括
普拉瓦斯塔丁在3年内显著减少了老年人的心血管事件. 这项研究将他类药物治疗的好处扩展到老年人群中,证明了它在预防心脏病方面的有效性.
科学领域:
- 心脏病学 心脏病学
- 老年病的医生 老年病的医生
- 药理学 药理学是指药理学的学科.
背景情况:
- 已经证明,他类药物可以减少中年人的心血管和脑血管事件.
- 在老年人群中,他类药物的疗效和安全性仍然不太确立.
- 这项研究调查了对心血管疾病和中风风险较高的老年人普拉瓦斯塔丁的益处.
研究的目的:
- 评估普拉瓦斯塔丁在减少老年男性和女性心血管和脑血管事件方面的有效性.
- 评估普拉瓦斯塔丁在这个人口群体中的安全性.
主要方法:
- 一项随机对照试验,涉及5804名年龄在70-82岁之间的参与者.
- 参与者接受了普拉瓦斯塔丁 (40毫克/天) 或安慰剂.
- 主要终点是冠状动脉死亡,非致命的心肌梗塞和致命或非致命性中风的组合,平均随访时间为3.2年.
主要成果:
- 普拉瓦斯塔丁降低了34%的LDL胆固醇,并显著降低了初级终点发生率 (HR 0.85,p=0.014).
- 冠心病死亡和非致命心肌梗塞风险降低 (HR 0.81,p=0.006).
- 虽然中风风险没有受到影响,但过渡性缺血性发作风险呈现下降趋势 (HR 0.75,p=0.051). 普拉瓦斯塔丁的使用与更高的新癌症诊断发病率有关,但分析没有显示整体风险增加.
结论:
- 长达3年的普拉瓦斯塔丁治疗有效降低了老年人冠状动脉疾病的风险.
- 这些发现支持将目前的他类药物治疗策略扩展到老年人群中.
- 在这个队列中,普拉瓦斯塔丁对认知功能或残疾没有显著影响.
更多相关视频
09:38Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
06:58Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing
Published on: January 24, 2020
相关概念视频
01:13Randomized Experiments
The randomization process involves assigning study participants randomly to experimental or control groups based on their probability of being equally assigned. Randomization is meant to eliminate selection bias and balance known and unknown confounding factors so that the control group is similar to the treatment group as much as possible. A computer program and a random number generator can be used to assign participants to groups in a way that minimizes bias.
Simple randomization
Simple...
Simple randomization
Simple...
01:15Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
01:00Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...